Fig. 5: Monovalent and bivalent adapted JN.1 vaccines induce nAbs against JN.1 and KP.2, KP.3 and XEC subvariants in booster immunization schedules. | npj Vaccines

Fig. 5: Monovalent and bivalent adapted JN.1 vaccines induce nAbs against JN.1 and KP.2, KP.3 and XEC subvariants in booster immunization schedules.

From: Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity

Fig. 5: Monovalent and bivalent adapted JN.1 vaccines induce nAbs against JN.1 and KP.2, KP.3 and XEC subvariants in booster immunization schedules.

BALB/c mice were i.m. immunized on days 0 and 14 with mRNA XBB.1.5 vaccine (Spikevax) and boosted on day 75 with: ARVAC JN.1 (n = 6), ARVAC XBB.1.5 (n = 6), ARVAC Gamma/Omicron BA.4/5 (n = 6) and ARVAC Gamma/JN.1 (n = 6) or Spikevax XBB.1.5 (n = 6). a Neutralizing-antibody titers against XEC, KP.2, KP.3, JN.1, XBB.1.5, Omicron BA.5, Gamma and Ancestral SARS-CoV-2 were evaluated at 75 (preboost) and 103 dpp (postboost). Neutralization titer was defined as the serum dilution that reduces 50% the cytopathic effect (NT50). Bars are GMT ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Kruskal–Wallis test. b Radar charts were drawn based on the geometric mean titers (GMTs) of neutralizing antibody in serum pre and post boost against live viruses for each vaccinated group.

Back to article page